Description
latin name
Dalacin
Indications
Acne vulgaris.
Contraindications
Hypersensitivity to clindamycin, lincomycin, or any component of the drug Dalacin.
Use during pregnancy and lactation
Adequate and well-controlled studies on the use of the drug in the first trimester of pregnancy have not been conducted. The use of Dalacin in the first trimester of pregnancy is possible only if the intended benefit outweighs the potential risk to the fetus.
When using clindamycin preparations in the II and III trimesters of pregnancy in dosage forms for intravaginal administration, there was no increase in the frequency of congenital malformations of the fetus. If Dalacin is used in the II and III trimesters of pregnancy (although there have been no official studies on the use of suppositories during pregnancy), an unfavorable effect on the fetus is unlikely.
There are currently no data on the excretion of clindamycin with breast milk with intravaginal administration of dalacin. However, it was found that when clindamycin is administered orally or parenterally, a certain amount is found in breast milk. Therefore, when deciding on the possibility of prescribing Dalacin during lactation (breastfeeding), the expected benefit for the mother and the possible risk for the child should be compared.
Dosage and administration
A thin layer of the gel is applied to the affected area of the skin, previously cleaned and dried 2 times a day.
Course of treatment: to obtain satisfactory results, therapy should be continued for 6 8 weeks, and if necessary, can be continued for up to 6 months.
Side effects
The incidence of the side effects listed below is less than 10%.
From the reproductive system: irritation of the mucous membrane of the vulva and vagina, vaginal pain, vaginal discharge, vaginal candidiasis, vulvovaginitis, trichomonas vaginitis, vaginal infections, menstrual irregularities, uterine bleeding, abnormal births, endometriosis.
From the urinary system: dysuria, urinary tract infections (including pyelonephritis), proteinuria.
From the digestive system: generalized abdominal pain, localized abdominal pain, abdominal cramps, bloating, dyspepsia, nausea, vomiting, diarrhea, constipation, flatulence, halitosis, taste perversion.
From the side of the central nervous system: dizziness, headache.
Dermatological reactions: rash, pruritus, maculopapular rash, erythema, skin candidiasis.
Allergic reactions: urticaria.
From the endocrine system: glucosuria, hyperthyroidism.
On the part of the body as a whole: fungal infections, fever, side pain, back pain, lower abdominal pain, generalized pain, bacterial infections, inflammatory edema, upper respiratory tract infections, nosebleeds, deviation of the results of microbiological analyzes from normal.
Local reactions: itching and pain at the injection site.
Drug Interaction
In vitro, an antagonistic interaction between clindamycin and erythromycin has been demonstrated.
It has been established that clindamycin disrupts neuromuscular transmission during systemic administration, thus enhancing peripheral muscle relaxant action. This fact should be taken into account when appointing the latter with Dalacin.
No interactions were observed in pharmacodynamic, pharmacokinetic or clinical studies of these dosage forms.
Overdose
With intravaginal use, absorption of clindamycin is possible in sufficient quantities to develop systemic reactions.
Accidental hit of the drug in the gastrointestinal tract can also cause systemic effects similar to those that occur after clindamycin taken at therapeutic doses. Possible systemic side effects include diarrhea, hemorrhagic diarrhea, including pseudomembranous colitis.
Treatment: if necessary, conduct symptomatic and supportive therapy.
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C. Do not freeze.
Expiration
2 years.
pharmacy terms and conditions without a prescription
Dosage Form A dosage form for external
gel
